Cargando…

Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML)

Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment modality for patients with acute myeloid leukemia (AML). Here, we investigated the predictive value of spleen volume on outcome parameters and engraftment kinetics after HSCT in a large cohort of AML patients. A tota...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pohlmann, Alexander, Bentgens, Eva, Schülke, Christoph, Kuron, David, Reicherts, Christian, Marx, Julia, Angenendt, Linus, Mikesch, Jan-Henrik, Lenz, Georg, Stelljes, Matthias, Schliemann, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444671/ https://www.ncbi.nlm.nih.gov/pubmed/37428201 http://dx.doi.org/10.1007/s00277-023-05353-9

Ejemplares similares

Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis
por: Kuron, David, et al.
Publicado: (2023)

Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Angenendt, Linus, et al.
Publicado: (2020)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Shaforostova, Inna, et al.
Publicado: (2023)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations
por: Brabetz, Oliver, et al.
Publicado: (2017)

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
por: Berdel, Andrew F., et al.
Publicado: (2022)

Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia
por: Wenge, Daniela V., et al.
Publicado: (2022)

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
por: Wullenkord, Ramona, et al.
Publicado: (2020)

Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma
por: Eisfeld, Christine, et al.
Publicado: (2020)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
por: Sun, Ming, et al.
Publicado: (2023)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Ussmann, Jule, et al.
Publicado: (2023)

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Berdel, Andrew F., et al.
Publicado: (2022)

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
por: Schliemann, Christoph, et al.
Publicado: (2016)

Impact of intensified contact precautions while treating hematopoietic stem cell transplantation recipients during aplasia
por: Böing, Christian, et al.
Publicado: (2023)

The Burden of Survivorship on Hematological Patients—Long-Term Analysis of Toxicities after Total Body Irradiation and Allogeneic Stem Cell Transplantation
por: Oertel, Michael, et al.
Publicado: (2021)

MN1–Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells
por: Wenge, D V, et al.
Publicado: (2015)

Establishing the hematopoietic stem cell transplant (HSCT) in a developing country; the journey of HSCT in Semarang, Indonesia
por: Santosa, Damai, et al.
Publicado: (2020)

COVID-19 and HSCT (Hematopoietic stem cell transplant)
por: Strasfeld, Lynne
Publicado: (2022)

Fulminant isolated adenovirus hepatitis 5 months after haplo-identical HSCT for AML
por: Detrait, Marie, et al.
Publicado: (2015)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
por: Kayser, S, et al.
Publicado: (2016)

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
por: Oellerich, Thomas, et al.
Publicado: (2019)

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
por: Andersson, Borje S., et al.
Publicado: (2016)

Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells
por: Larrue, Clément, et al.
Publicado: (2021)

Extramedullary Relapse of the AML Transformed from MDS Following Auto-HSCT: A Case Report
por: Wang, Jin, et al.
Publicado: (2014)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
por: Wang, Luxiang, et al.
Publicado: (2023)

Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study
por: Caballero-Velázquez, Teresa, et al.
Publicado: (2023)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
por: Noviello, Maddalena, et al.
Publicado: (2019)

Vancomycin Pharmacokinetic Parameters in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
por: Ghehi, Maryam Taghizadeh, et al.
Publicado: (2013)

Lipid Complications after Hematopoietic Stem Cell Transplantation (HSCT) in Pediatric Patients
por: Bis, Gabriela, et al.
Publicado: (2020)

The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients
por: KARATAŞ, Ayşe, et al.
Publicado: (2021)

Endocrine Sequelae in 157 Pediatric Survivors of Hematopoietic Stem Cell Transplantation (HSCT)
por: Güemes, María, et al.
Publicado: (2022)

Hematopoietic Stem Cells Transplant (HSCT)-Related Chronic Pulmonary Diseases: An Overview
por: Traunero, Arianna, et al.
Publicado: (2023)

Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation
por: Cao, Weijie, et al.
Publicado: (2022)

A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy
por: Wass, Maxi, et al.
Publicado: (2020)

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT
por: Bohl, S, et al.
Publicado: (2016)

Single-Nucleotide Polymorphisms in MICA and MICB Genes Could Play a Role in the Outcome in AML Patients after HSCT
por: Machuldova, Alena, et al.
Publicado: (2021)

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022)

Hematopoietic stem cell transplantation (HSCT) as an example of personalized approach in the management of individual disease
por: Everaus, Hele
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_egi8qo69ht0cvnm5glivb00496